ArticleInternational journal of pharmaceutics: X2025
Transferrin conjugated pH/NIR-responsive black phosphorus nanoplatform: A novel multimodal approach for breast cancer theranostics.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is one of the foremost causes of death, posing a significant challenge to global health. Breast cancer is predominant cancer type in women globally. Nanotheranostic platforms have emerged as a promising strategy for enhancing breast cancer therapy by integrating both diagnostic and therapeutic functionalities. Black phosphorous nanosheets (BPNSs) are nanotheranostic 2D materials that can adsorb a large number as well as quantity of therapeutic or theranostic agents due to their greater surface area. Herein, the authors developed an efficient pH and NIR-responsive nanotheranostic drug delivery platform for synergistic chemo/photothermal/photodynamic therapy of breast cancer. The exfoliated BPNSs were surface loaded with an anticancer drug, doxorubicin (DOX), functionalized with a photo-responsive polymer, polydopamine (PDA), and conjugated with a protein-based ligand, transferrin (TF). The prepared BP-based nanoformulation demonstrated excellent photothermal stability, improved targeting efficiency and desired therapeutic activity. A pH/NIR-responsive nature was observed during in vitro DOX release studies with negligible toxicity during hemolysis and CAM assay. Cell line studies on 4 T1 cells showed NIR-specific toxicity compared to non-irradiated groups with excellent ligand-mediated cellular uptake. Furthermore, an increase in the amount of necrotic and apoptotic cells in 4 T1 cells with elevated ROS levels were observed. 4 T1-tumour bearing BALB/c mice models administered with BP-based nanoformulation indicated an efficient reduction in tumour volume in NIR-irradiated groups and enhanced pharmacokinetic parameters. In vitro and in vivo studies demonstrated that the synergistic approach of merging chemotherapy with photothermal and photodynamic therapy exhibits remarkable antitumour effectiveness, excellent biocompatibility, and promising competence for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.